ARTICLE | Clinical News
Bazedoxifene/conjugated estrogens regulatory update
July 23, 2012 7:00 AM UTC
Pfizer said EMA accepted for review an MAA for bazedoxifene/conjugated estrogens (BZA/CE) to treat symptoms associated with menopause and osteoporosis. The company said it expects a decision in 2013. ...